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Alternative polyadenylation of ZEB1 promotes its
translation during genotoxic stress in pancreatic
cancer cells
Ilaria Passacantilli1,2, Valentina Panzeri1,2, Pamela Bielli1,3, Donatella Farini1, Emanuela Pilozzi2, Gianfranco Delle Fave2,
Gabriele Capurso2 and Claudio Sette*,1,3
Pancreatic ductal adenocarcinoma (PDAC) is characterized by extremely poor prognosis. The standard chemotherapeutic drug,
gemcitabine, does not offer significant improvements for PDAC management due to the rapid acquisition of drug resistance by
patients. Recent evidence indicates that epithelial-to-mesenchymal transition (EMT) of PDAC cells is strictly associated to early
metastasization and resistance to chemotherapy. However, it is not exactly clear how EMT is related to drug resistance or how
chemotherapy influences EMT. Herein, we found that ZEB1 is the only EMT-related transcription factor that clearly segregates
mesenchymal and epithelial PDAC cell lines. Gemcitabine treatment caused upregulation of ZEB1 protein through post-
transcriptional mechanisms in mesenchymal PDAC cells within a context of global inhibition of protein synthesis. The increase in
ZEB1 protein correlates with alternative polyadenylation of the transcript, leading to shortening of the 3' untranslated region (UTR)
and deletion of binding sites for repressive microRNAs. Polysome profiling indicated that shorter ZEB1 transcripts are specifically
retained on the polysomes of PDAC cells during genotoxic stress, while most mRNAs, including longer ZEB1 transcripts, are
depleted. Thus, our findings uncover a novel layer of ZEB1 regulation through 3'-end shortening of its transcript and selective
association with polysomes under genotoxic stress, strongly suggesting that PDAC cells rely on upregulation of ZEB1 protein
expression to withstand hostile environments.
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Pancreatic ductal adenocarcinoma (PDAC) is among the
deadliest human cancers, with rate of overall survival at 5
years from diagnosis being less than 5%.1 Late diagnosis
and the highly metastatic behavior of PDAC cells substan-
tially contribute to such poor prognosis.2 Moreover, despite
improvement in surgical techniques and introduction of novel
chemotherapeutic approaches, PDAC patients rapidly
develop resistance to therapies and progress to advanced,
incurable stages.
Epithelial-to-mesenchymal transition (EMT), namely the
ability of an epithelial cell to acquire a fibroblast-like shape,
is among the biological processes promoting metastatic
dissemination of epithelial cancers, including PDAC.3,4 EMT
is a physiological process that underlies cell migration and
organ colonization in the developing embryo. However, it can
be re-activated upon neoplastic transformation of epithelial
cells, permitting them to reach distal tissues and to give rise to
metastasis.5,6 In PDAC mouse models, EMT allows dissemi-
nation of cancer cells even before the primary tumor is fully
visualized.7 Furthermore, acquisition of the mesenchymal
phenotype seems to be related to drug resistance of PDAC
cells,8-11, in particular to gemcitabine, the standard first-line
treatment for PDAC. However, the specific molecular mechan-
isms by which the mesenchymal phenotype contributes to
chemoresistance are not fully understood.
EMT is driven by global gene expression re-programming
operated by transcription factors (TFs), such as ZEB1, ZEB2,
SNAIL, SLUG and TWIST.12 All these TFs activate transcrip-
tion of mesenchymal genes while repressing epithelial genes.
However, emerging evidence strongly suggests that not all
EMT programs are equal in vivo. Indeed, studies using PDAC
mouse models clearly showed that EMT triggered by ZEB1
promotes cell plasticity and metastasis,13whereas SNAIL and
TWIST had no effect on invasion or metastasis while they
favored resistance to chemotherapy.11 Furthermore, ZEB1
was shown to play a key role in early dissemination of PDAC
cells.7 Thus, regulation of ZEB1 expression is highly relevant
for PDAC onset and progression.
Genotoxic stress elicited by most chemotherapeutic drugs
often turns on pro-survival pathways that result in selection of
resistant cells. Modulation of post-transcriptional pre-mRNA
processing is a key step in the fine-tuned regulation of gene
expression programs during both EMT and acquisition of drug
resistance.6,14 In the present work, we found that gemcitabine
induces an increase in ZEB1 protein expression in mesenchy-
mal PDAC cell lines, which occurred concomitantly with global
inhibition of protein synthesis. Cell fractionation experiments
showed that while most mRNAs are released from the
polysomes following the translational block, ZEB1 mRNA
remains associated with them. Mechanistically, gemcitabine
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treatment promoted alternative polyadenylation of ZEB1mRNA,
leading to shortening of its 3' untranslated region (UTR). This
shorter ZEB1 transcript variant was more efficiently associated
with polysomes than longer ZEB1 transcripts in cells exposed to
the drug. Our findings highlight a novel mechanism involved in
ZEB1 regulation in response to genotoxic stress and suggest
that its enhanced expression offers an opportunity to PDAC cells
to survive to the insult while priming them for metastatic spread.
Results
Gemcitabine treatment enhances ZEB1 expression in
mesenchymal PDAC cell lines. Mesenchymal phenotype
has been associated with resistance to chemotherapy in
PDAC.8–11 Accordingly, colony formation assays indicated
thatPt45P1 and MiaPaCa-2 PDAC cells, which express the
mesenchymal marker Vimentin (Supplementary Figures S1A,
B), were significantly more resistant to low dosage (0.01 μM)
of gemcitabine than the HPDE immortalized epithelial ductal
cells and HPAF-II PDAC cells (Supplementary Figure S1C),
which both display an epithelial phenotype and express
E-cadherin (Supplementary Figures S1A,B). At increasing
doses (0.03–0.1 μM), Pt45P1 cells showed higher sensitivity
than MiaPaCa-2 (Supplementary Figure S1C). Likewise,
cleavage of full length PARP-1 also showed higher sensitivity
to apoptosis of epithelial HPAF-II cells with respect toPt45P1
and MiaPaCa-2cells (Supplementary Figure S1D), confirming
the correlation between drug resistance and the mesenchy-
mal phenotype in PDAC cell lines.
To investigate which EMT-related TF was differentially
expressed in PDAC cell lines, we performed conventional
(cPCR) and quantitative real-time PCR (qPCR) analyses.
Notably, only ZEB1 clearly segregated the mesenchymal
Pt45P1 and MiaPaCa-2 from the epithelial HPAF-II cells,
whereas SLUG and SNAIL were expressed at variable levels
regardless of the phenotype and TWIST levels were not
detectable (Figures 1a and b). Differential ZEB1 expression
between epithelial and mesenchymal PDAC cells was also
observed at the protein level (Figure 1c), confirming the
correlation with the gemcitabine-resistant phenotype of
these cells.
Poor prognosis in PDAC is mainly due to unresponsiveness
of patients to chemotherapy with gemcitabine, either as single
agent or in combination with other drugs.15 Given the role of
ZEB1 in PDAC cells drug resistance,9,13 we asked whether
genotoxic stress associated with chemotherapy affected its
expression. Treatment with gemcitabine for 48 h elicited a
significant upregulation of ZEB1 protein expression in both
Pt45P1 and MiaPaCa-2 cells (Figure 1d). Notably, such
increase was sustained over at least 72 h (Supplementary
Figure S1E) and not accompanied by significant upregulation
of ZEB1 mRNA (Figure 1e), nor by stabilization of the pre-
existing ZEB1 protein, as tested by incubation of cells with the
proteasome inhibitor MG132 (Figure 1f). These results
suggest that gemcitabine induces upregulation of ZEB1
expression by post-transcriptional mechanism(s).
Gemcitabine induces a global inhibition of protein
synthesis in PDAC cell lines. Acute chemotherapeutic
treatments often activate responses that facilitate survival of
cancer cells to genotoxic stress.16–19 To investigate the post-
transcriptional mechanism(s) underlying the increase in ZEB1
protein levels, we first monitored the impact of gemcitabine
treatment on the mTORC1 pathway, a regulatory route of
protein synthesis with strong relevance for human cancers.20 A
key target of the mTORC1 kinase is the inhibitory protein
4EBP1, which binds the translation initiation factor eIF4E and
prevents its assembly with eIF4G and the RNA helicase eIF4A
to form the translation initiation complex eIF4F.20 Phosphoryla-
tion of 4EBP1 by mTORC1 causes its release from eIF4E and
stimulates eIF4F assembly and cap-dependent translation.
Treatment with gemcitabine caused progressive inhibition of
4EBP1 phosphorylation in Pt45P1 and MiaPaCa-2cells by 24–
72 h, with increasing prevalence of the non-phosphorylated
form (γ) of 4EBP1 (Figure 2a). To confirm the effect of genotoxic
stress on the inhibition of cap-dependent translation, we
performed methyl-cap pulldown assays to isolate the eIF4F
complex.21 Drug treatment impaired association of eIF4A and
eIF4Gwith eIF4E on methyl-cap in both cell lines, whereas
binding of hypo-phosphorylated 4EBP1 was increased
(Figure 2b). In line with this effect, gemcitabine caused a global
decrease of mRNA loaded on polysome fractions while it
increased the peaks associated with monosomes (80S) and
free ribonucleoproteinparticles (RNPs), which are not engaged
in translation (Figure 2c). Thus, genotoxic stress triggered by
gemcitabine inhibits cap-dependent translation and generally
stalls protein synthesis in PDAC cells.
ZEB1mRNAis selectively maintained on polysomes dur-
ing genotoxic stress. Since upregulation of ZEB1 in PDAC
cells occurred in a context of global protein synthesis
inhibition, we specifically analyzed the profile of ZEB1 mRNA
distribution in polysome fractionation experiments.ZEB1
transcript, like those of the housekeeping genes HPRT and
GAPDH, was almost equally distributed between polysome
and RNP fractions in control cells, and this pattern was not
substantially affected by 12 h treatment with gemcitabine
(Figures 3a and b). However, while prolonged exposure to the
drug (48 h) caused a drastic decrease in polysomal loading of
the HPRT and GAPDH mRNAs, ZEB1 mRNA was actively
retained on polysomes with respect to the free RNP fraction
(Figures 3a and b). Notably, this regulation was specific for
ZEB1, as transcripts of other EMT-related TFs (SLUG and
SNAIL) behaved like HPRT and GAPDH mRNAs and in line
with the global decrease of mRNA translation (Figures 3a and
b). Quantitative analyses by qPCR confirmed that treatment
with gemcitabine significantly increased the polysome/RNP
ratio for ZEB1 mRNA (Figure 3c) while decreasing that of
HPRT and GAPDH mRNAs.
Polysomal recruitment of mRNAs upon inhibition of cap-
dependent translation can be mediated by internal ribosome
entry segments (IRES)-mediated translation.22 IRES are
structured sequences located in the 5′UTR of mRNAs and
promote ribosome recruitment. Search in the Ensemble
database (http://www.ensembl.org/index.html) revealed anno-
tation of two classes of 5′UTR for ZEB1 transcripts encoded by
alternative first exons. Exon 1-containing transcripts encode for
short 5′ UTRs with unstructured nucleotide sequence
(ENST00000320985.14, 100 bp; ENST00000560721.6,
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22 bp; ENST00000542815.7, 71 bp; ENST00000361642.9,
63 bp), whereas exon 1C encodes a longer, structured 5′
UTR of 392 nucleotides (ENST00000446923.6) that resembles
an IRES sequence (Supplementary Figure S2A). To test
whether this sequence acted as IRES, we inserted it into the
intercistronic region of the pRF construct, which contains the
Renilla and Firefly luciferase genes as upstream and down-
stream cistrons, respectively (Supplementary Figure S2B).23
Transfection of this construct into MiaPaCa-2 cells indicated
that, unlike the Myc IRES element, the exon 1C-encoded
sequence was unable to induce expression of the downstream
cistron regardless of gemcitabine treatment (Supplementary
Figure S2B), suggesting that it does not possess IRES activity.
Accordingly, we found that ZEB1 transcripts containing this
longer 5′UTRwere not selectively retained on polysomes upon
treatment with gemcitabine (Supplementary FigureS2C). Thus,
alternative 5′ UTR usage and/or IRES-dependent translation
are unlikely responsible for the increased translation of ZEB1
upon gemcitabine-induced stress.
Alternative polyadenylation of ZEB1 supports its transla-
tion upon genotoxic stress. Translation regulation can be
also modulated by changes in the 3′ UTR of target mRNAs,
which result from alternative polyadenylation (APA)
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Figure 1 Gemcitabine induces upregulation of ZEB1 protein in mesenchymal PDAC cells. Conventional (a) and quantitative (b) RT-PCR analysis of ZEB1, SLUG, SNAIL and
TWIST mRNA expression in the indicated PDAC cell lines. HPRT was used as housekeeping gene for normalization. (c) Western blot analysis of ZEB1 protein expression in the
indicated PDAC cell lines. Coomassie blue staining was performed as sample loading control. (d) Western blot and (e) quantitative RT-PCR of ZEB1 expression in Pt45P1 and
MiaPaCa-2 cells treated or not with gemcitabine (10 μM) for 48 h. (f) Western blot analysis of ZEB1 protein expression in MiaPaCa-2 cells treated or not with gemcitabine (10 μM)
for 48 h. MG132 was added to cells in the last 8 h of treatment. Bar graphs in (b), (d) and (e) represent the mean±S.D. of three experiments. * Po0.05; n.s.= not significant
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regulation.24 Three main alternative polyadenylation signals
(PAS) are present in the ZEB1 last exon (indicated as p1–p3
from proximal to distal in Figure 4a). Notably, binding sites for
microRNAs that repress ZEB1 expression by targeting its 3′
UTR (miR-200 family and miR-205)9,25 are located between
the p1 and p2 PAS (Figure 4a).By using reverse primers
located upstream of the p1, p2 or p3 PAS, we observed that
treatment of MiaPaCa-2 cells with gemcitabine caused
shortening of the 3'UTR of ZEB1, with selective decrease
of transcripts terminating at the p2 and p3 PAS (Figure 4b). To
verify that shortening was due to APA regulation, we
performed 3'-RACE experiments in MiaPaCa-2 cells treated
or not with gemcitabine. Drug treatment caused reduced
termination of the ZEB1 transcript at the p2 PAS, without
affecting termination at the p1 PAS (Figure 4c). Sequencing
of the PCR product verified the presence of a PAS at the p2
region and polyadenylation (Figure 4d), thus confirming that
ZEB1 APA regulation is sensitive to stress.
Next, we asked whether APA resulted in differential
polysomal loading of ZEB1 alternative transcripts. Polysome
fractionation experiments in control and gemcitabine-treated
samples revealed that the p1/p2 ratio and p1/p3 ratio were
significantly increased in the polysome fraction and reduced in
the RNP fraction obtained from MiaPaCa-2 cells treated with
gemcitabine (Figure 4e). These experiments indicate that
gemcitabine causes a general shortening of the 3'UTR of
ZEB1, and that transcripts containing the shorter 3'UTR are
more efficiently retained on polysomes than longer transcripts
during genotoxic stress in PDAC cells.
Discussion
Cancer cells display remarkable adaptability to adverse
environments, which likely contributes to acquisition of
resistance to therapeutic treatments.18 This is particularly true
for PDAC cells and manifests in the failure of efficacious
therapies for patients after years of efforts and research in the
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field.2,15 One feature that is related to the refractoriness of
PDAC cells to treatments is their plasticity. Indeed, acquisition
of a mesenchymal phenotype by epithelial PDAC cells is
thought to be responsible for both metastatic behavior and
resistance to chemotherapy.7-11,13, Although EMT can be set
in motion by several TFs,12 ZEB1 plays a unique and
prominent role in PDAC metastasization and resistance to
treatments.13 Nevertheless, how and when ZEB1 expression
is altered in response to chemotherapy is still largely unknown.
Herein, we found that upregulation of ZEB1 expression is an
early event in such response, which occurs within 24–48 h
from exposure of PDAC cells to gemcitabine. Importantly,
ZEB1 upregulation is driven by a post-transcriptional mechan-
ism that occurs in the absence of changes in ZEB1 transcript
levels and in a general context of translational inhibition.
In this scenario, while most mRNAs are depleted from the
polysomes, ZEB1 transcripts remain associated with the
translational machinery and likely insure continuous transla-
tion of this key TF under gemcitabine-elicited genotoxic stress.
Thus, our findings suggest that the peculiar post-
transcriptional regulation of ZEB1 expression represents a
feedback mechanism set in motion by mesenchymal PDAC
cells to withstand adverse conditions caused by
chemotherapy.
Protein synthesis is an energy-consuming process and cells
tune it down under various types of stress, including genotoxic
stress elicited by most chemotherapeutic drugs.22Neverthe-
less, some proteins are instrumental to survive under stress
conditions and need to be translated. In most cases,
regulation of translation under stress is conferred by the 5'
and 3'UTR of target transcripts. In our study, we provide
evidence that changes in the 3'UTR of ZEB1 contribute to its
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Figure 3 ZEB1mRNAis selectively maintained on polysomes during genotoxic stress. (a) Absorbance profiles of fractions obtained on sucrose gradients to isolate polysomes
from monosome (80S) and free RNPs in MiaPaCa-2 cells treated or not with 10 μM gemcitabine for 12 h (left panel) or 48 h (right panel). (b) Conventional RT-PCR analysis of the
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sustained expression upon genotoxic stress. It is well
established that many microRNAs elicit translational repres-
sion by binding to complementary sequences in the 3'UTR of
target transcripts. Recent evidence suggests that most human
3'UTR sequences contain more than one PAS and that
alternative PAS selection leads to expression of multiple
transcript variants through APA.24 In general, progressive
shortening of the 3'UTR through selection of proximal PASs
should relieve repression by microRNAs and promote
translation. Accordingly, it has been observed that global
3'UTR shortening correlates with high proliferative rates
whereas lengthening occurs during cell differentiation.24The
3'UTR of ZEB1 is particularly long (~2500 nucleotides) and
contains putative binding sites for many microRNAs, including
members of the miR-200 family that repress its expression in
cancer epithelial cells.25 Genotoxic stress caused shortening
of the 3'UTR, with selective depletion of transcripts terminating
at the distal PASs (p2 and p3) in cells treated with gemcitabine.
Notably, most of the microRNA binding sites, including all the
sites for the repressive miR-200 members, map between p1
and p2. APA leading to shortening of the 3'UTR should
relieve translational repression of ZEB1 by these microRNAs.
In line with this hypothesis, treatment with gemcitabine
differentially affected the association of ZEB1 transcript
variants with polysomes, with proportional increase in those
terminating at p1 and corresponding depletion of transcripts
terminating at p2 and p3. Thus, progressive shortening of the
ZEB1 transcript may promote its translation by removing
inhibition by microRNAs and favoring its recruitment onto
polysomes. Since ZEB1 and miR-200 members are under
mutual control in a negative feedback loop,9we suggest that
this mechanism may rapidly shift the balance in favor of
ZEB1 and mesenchymal features in PDAC cells exposed to
gemcitabine.
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APA is regulated by changes in the activity and/or
expression of key components of the cleavage and poly-
adenylation complex, which often cooperate with accessory
RNA binding proteins (RBPs) that bind elements located near
the regulated PAS.24 Some of these RBPs, like Sam68 and
hnRNPH, are often upregulated in human cancers and can
suppress or enhance recognition of cryptic PASs depending
on the context.26,27Notably, localization and function of
Sam68,28 as well as many other RBPs,18,29 is regulated upon
genotoxic stress. Thus, it is possible that gemcitabine-induced
stress promotes the recruitment of specific RBPs to the ZEB1
transcript, thereby affecting the choice of the proximal PAS
and enhancing translational efficiency. Alternatively, APA is
also modulated by the rate of transcription.24 Changes in the
phosphorylation status of the RNA polymerase II (RNAPII)
affect its elongation rate within the transcription unit and its
pausing at PAS. Thismodulation of RNAPII dynamics can alter
the time window for PAS recognition and usage.24 More
recently, it has also been shown that reduced expression of
RNAPII upon several stresses, including DNA damage,
switches APA regulation from the preferred PAS to alternative
ones in selected transcripts.30 In this regard, gemcitabine is
known to reduce the transcriptional activity of PDAC cells16
and might contribute to the switch in ZEB1 APA by
concomitantly regulating RNAPII expression or function and
depleting endogenous nucleotides due to interference with
their biosynthesis. These observations suggest that further
mechanistic studies will be required to dissect the exact
mechanism(s) involved in ZEB1 APA regulation during
genotoxic stress. Furthermore, since ZEB1-driven EMT is
particularly efficient to confer the highly aggressive and
resistant phenotype typifying PDAC cells,13 our findings also
suggest that development of tools to alter APA in ZEB1 may
help sensitizing PDAC cells to genotoxic stress.
Materials and Methods
Cell culture, treatments and tranfections. HPDE, HPAF-II and Pt45P1
were cultured in RPMI 1640 medium (Lonza, Switzerland) supplemented with 10%
fetal bovine serum (Gibco Thermo Fisher, Waltham, MA, USA), MiaPaCa-2 cells
were cultured in DMEM medium (Lonza) supplemented with 10% fetal bovine
serum (Gibco). Cells were grown in a 37 °C humidified atmosphere of 5% CO2.
Gemcitabine (Eli Lilly & Company, Indianapolis, IN, USA) was dissolved in water
and stored at − 20 °C.
RT-PCR and qPCR analysis. Total RNA was extracted from cells using
Trizol reagent (Invitrogen Thermo Fisher, Waltham, MA, USA) according to the
manufacturer’s instructions. After digestion with RNase free DNase (Ambion
Thermo Fisher, Waltham, MA, USA), RNA was resuspended in RNase free water
(Sigma-Aldrich, St. Louis, MO, USA); 1 μg of total RNA was retrotranscribed using
M-MLV reverse transcriptase (Promega, Madison, WI, USA). Five percent of the
reaction was used as template for RT-PCR analysis (GoTaq, Promega) or qPCR
analysis (SYBR Green method, Roche, Germany). Primers used are listed in
Supplementary Table S1.
Protein extraction and western blot analysis. Cells were resuspended
in lysis buffer (100 mM NaCl, 15 mM MgCl2, 2 mM EDTA, 20 mM Hepes, 10%
Glycerol, 1 mM dithiothreitol, 2 mM Na-ortovanadate, Protease-Inhibitor Cocktail
(Sigma-Aldrich) and 1% Triton X-100). After10 min of incubation in ice, extracts
were centrifuged for 10 min at 12 000 rpm at 4 °C, supernatants were resuspended
in SDS-page sample buffer and boiled for 5 min. Western blot analysis was
performed as previously described.31 The following primary antibodies (overnight
at4 °C) were used: rabbit anti-Actin (1 : 1000, Sigma-Aldrich), mouse anti-GAPDH
(1 : 1000, Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-E-cadherin
(1 : 1000, Santa Cruz Biotechnology), mouse anti-Vimentin (1 : 1000, Santa Cruz
Biotechnology), rabbit anti-ZEB1 (1 : 1000, Sigma-Aldrich), rabbit anti-eiF4E
(1 : 1000, Cell Signalling Technology, Danvers, MA, USA), rabbit 4EBP1
(1 : 1000, Cell Signalling Technology), rabbit anti PARP-1 (1 : 1000, Cell Signalling
Technology), rabbit anti eiF4A (1 : 1000, Abcam, UK), rabbit anti-eIF4G (1 : 1000,
Cell Signalling Technology). Secondary anti-mouse or anti-rabbit IgGs conjugated to
horseradish peroxidase (Amersham, UK) were incubated for 1 h at RT (1 : 10 000).
Immunostained bands were detected by chemiluminescence method (Santa Cruz
Biotechnology).
Colony formation assay. Single-cell suspensions were plated in 35 mm
plates (500 cells/plate for Pt45P1 andMiaPaCa-2; 700 cells/plate for HPDE and
HPAF-II). After 1 day, cells were treated for 24 h with gemcitabine at the dose
indicated. At the end of the incubation, the medium was replaced every 48 h. After
10 days, cells were fixed in methanol for 10 min, stained overnight with 5% Giemsa
(Sigma-Aldrich), washed twice in PBS and dried. Pictures were taken using a digital
camera to count and measure the colonies. Results represent the mean of at least
three experiments± s.d.
Polysomes-RNPs fractionation by sucrose gradients. Polysomes
fractionation was performed as indicated previously.21,32 Briefly, MiaPaCa-2 cells were
homogenized in lysis buffer (100 mM NaCl, 10 mM MgCl2, 30 mM Tris-HCl [pH 7.5],
1 mM DTT, 30 U/ml RNasin) supplemented with 1% Triton X-100. After 5 min of
incubation on ice, the lysates were centrifuged for 10 min at 12 000 × g at 4 °C. The
supernatants (1.5 mg of protein extracts) were loaded on a 15–50% (wt/vol) sucrose
gradients and sedimented by centrifugation for 110 min at 37 000 r.p.m. in a Beckman
SW41 rotor (Fullerton, CA, USA). Each gradient was collected in 10 fractions, RNA
was extracted by phenol/chloroform method. Fractions 1–5 (Polysomes) and 8–10
(RNPs) were pulled and analyzed by RT-PCR and qPCR methods.
3′ RACE PCR. Total RNA (1 μg) was used for retrotranscription with 0.5 μg of
oligo oligo-dT tail followed by an anchor sequence.26 PolyA enriched/anchor tagged
cDNA was subsequently used in RT-PCR experiments using gene-specific forward
primers in presence of anchor reverse primer.
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